Overview

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Status:
Recruiting

Trial end date:
2024-10-25

Target enrollment:

Participant gender:

Summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or second-line treatment for locally advanced unresectable/metastatic TNBC.

Phase:

Phase 3

Details

Lead Sponsor:

G1 Therapeutics, Inc.

Treatments:

Carboplatin
Gemcitabine